Abstract
A wave of terminations of development programmes for cannabinoid receptor 1 blockers for obesity indicates the demise of a drug class that was once anticipated to yield blockbusters. Nevertheless, lessons learned might help salvage something for future such approaches.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Role of cannabinoid receptor 1 in human adipose tissue for lipolysis regulation and insulin resistance
Endocrine Open Access 17 November 2016
-
Current and Future Drug Targets in Weight Management
Pharmaceutical Research Open Access 23 December 2010
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Jones, D. End of the line for cannabinoid receptor 1 as an anti-obesity target?. Nat Rev Drug Discov 7, 961–962 (2008). https://doi.org/10.1038/nrd2775
Issue Date:
DOI: https://doi.org/10.1038/nrd2775
This article is cited by
-
Nanoplatform based on GSH-responsive mesoporous silica nanoparticles for cancer therapy and mitochondrial targeted imaging
Microchimica Acta (2021)
-
Cannabinoids in Metabolic Syndrome and Cardiac Fibrosis
Current Hypertension Reports (2020)
-
Role of cannabinoid receptor 1 in human adipose tissue for lipolysis regulation and insulin resistance
Endocrine (2017)
-
Discovery of new lead pyrimidines derivatives as potential cannabinoid CB1 receptor antagonistic through molecular modeling and pharmacophore approach
Medicinal Chemistry Research (2014)
-
Rimonabant Redux and Strategies to Improve the Future Outlook of CB1 Receptor Neutral‐Antagonist/Inverse‐Agonist Therapies
Obesity (2011)